<DOC>
	<DOCNO>NCT00291356</DOCNO>
	<brief_summary>This study compare safety , blood concentration , effect GSK189075 , GW869682 , placebo dose 2-weeks mouth patient type 2 diabetes .</brief_summary>
	<brief_title>GSK189075 , GW869682 Or Placebo In Type 2 Diabetic Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Inclusion criterion : Type 2 diabetes . HbA1c ( measure average amount sugar blood last 2 3 month ) level 7.0 9.0 . Taking 850mg per day metformin , take diabetes medication . Must medically able willing discontinue diabetic medication least 2 week prior first study dose last study assessment . Diabetic subject yet start take diabetes medication whose diabetes control diet alone may also eligible enroll HbA1c within 7.5 9.0 . Women may eligible postmenopausal surgically sterile . If take ACE inhibitor , betablockers , calcium channel blocker , statin type drug , may eligible dose stable least 30 day prior start clinical trial . Exclusion criterion : Using illicit drug , antibody hepatitis B , hepatitis C , HIV . Have major health problem type 2 diabetes . Require insulin therapy oral antidiabetic medication metformin . Subjects urinary tract infection within 4 week start study kidney disease . Subjects either low high blood pressure . Men unwilling abstain intercourse , use condom pregnant nursing female , unwilling use condom another form contraception female could become pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>sodium dependent glucose transporter</keyword>
	<keyword>SGLT2</keyword>
	<keyword>GSK189075</keyword>
	<keyword>GSK189074</keyword>
	<keyword>SGLT1</keyword>
	<keyword>GW869683</keyword>
</DOC>